TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Scheme of Arrangement
Intimation for approval of scheme of amalgamation of Curatio Health Care (I) Private Limited with Company21-12-2022
21-12-2022
TORRENT PHARMACEUTICALS LTD. - 500420 - Closure of Trading Window
Intimation of the Closure of Trading Window as per Company''s Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons15-12-2022
TORRENT PHARMACEUTICALS LTD. - 500420 - Partial Redemption Of Non-Convertible Debentures
Partial Redemption of Non-Convertible Debentures14-12-2022
Torrent Pharma, Boehringer Ingelheim India to co-market diabetes drug
Torrent Pharmaceuticals on Wednesday said it has inked a pact with Boehringer Ingelheim India to co-market diabetes drug and its combinations in the country. The company has inked an agreement to jointly sell Cospiaq (Empagliflozin), Cospiaq Met (Empagliflozin+ Metformin) and Xilingio (Empagliflozin+ Linagliptin). Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus. It is also indicated to reduce the risk of cardiovascular death, in adults with type 2 diabetes mellitus and established cardiovascular disease. "I am confident that the launch of Cospiaq, Cospiaq Met and Xilingio will further strengthen our overall diabetes and cardiovascular portfolios and bolster our position as a leading player in these high growth segments within the Indian pharmaceutical market," Torrent Pharmaceuticals Director Aman Mehta said in a statement. Boehringer Ingelheim India Managing Direct14-12-2022
TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Torrent Pharmaceuticals Ltd enters into co-marketing partnership with Boehringer Ingelheim India Private Limited to co- market its anti-diabetic drug and its fixed dose combinations in India14-12-2022
TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper advertisement in respect of the transfer of shares to IEPF08-12-2022
TORRENT PHARMACEUTICALS LTD. - 500420 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Loss of Share Certificates06-12-2022
TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Investors Meet under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201514-11-2022
TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Issue of Securities
Intimation regarding issue of Non-Convertible Debentures on Private Placement basis09-11-2022
TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Credit Rating
Pursuant to Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, it is hereby informed that India Ratings and Research Private Limited has affirmed / assigned the rating on various instruments of the Company. The rating letter issued by the India Ratings and Research Private Limited is enclosed herewith.04-11-2022